Pro-Inflammatory cytokines & neurobehavioral symptoms in breast cancer patients

描述（由申请人提供）：乳腺癌妇女的促炎细胞因子和神经行为症状。摘要乳腺癌的幸存者报告了使人衰弱的行为症状，如疲劳和神经认知功能障碍，即使在治疗前的基线，这些症状在某些个体中也很明显。来自不同研究领域的足够证据表明，癌症相关的神经行为症状可能至少部分由促炎细胞因子网络的激活驱动。乳腺癌患者治疗前获得的血清中特异性促炎细胞因子（IL-6、TNF）和可溶性受体的浓度显著高于健康个体中发现的水平，并具有预后价值;然而，尚未评价这些治疗前升高与急性或慢性行为症状的相关性。在乳腺癌幸存者中，循环sIL-6 R和IL-1 ra水平升高已成为化疗后数年女性的横断面研究中持续疲劳的突出生物标志物。没有类似的工作已经确定了该患者群体中神经认知功能障碍的生物标志物，并且尚不清楚细胞因子与疲劳或其他行为症状的联系是否存在于更接近诊断期或随着时间的推移而演变为“晚期效应”。在这项研究中，我们将解决这一知识差距，因为我们将在癌症治疗前评估这种关联，并在治疗完成后再次评估。我们将在至少137例乳腺癌患者中比较这些相关性，并在治疗前与两个对照组进行比较，并在治疗后仅对乳腺癌组进行纵向评估。这些发现有望增加我们对乳腺癌患者神经行为症状相关的可能生物标志物的了解，以便更好地识别和治疗那些有这种影响风险的人。公共卫生相关性：研究结果有望增加对乳腺癌患者神经行为症状相关的可能生物标志物的了解，以便更好地识别和治疗那些有这种影响风险的人。

DESCRIPTION (provided by applicant): Pro-inflammatory cytokines and neurobehavioral symptoms in women with breast cancer. Abstract Survivors of breast cancer report debilitating behavioral symptoms, such as fatigue and neurocognitive dysfunction, which are evident in some individuals even at pre-treatment baseline. There is sufficient evidence from varied lines of research to propose that cancer-related neurobehavioral symptoms may be driven, at least in part, by activation of the pro-inflammatory cytokine network. Concentrations of specific pro-inflammatory cytokines (IL-6, TNF) and soluble receptors in serum obtained prior to treatment in breast cancer patients are significantly higher than levels found in healthy individuals and have prognostic value; however, these pre- treatment elevations have not yet been evaluated with respect to their association with either acute or chronic behavioral symptoms. Among survivors of breast cancer, elevated levels of circulating sIL-6R and IL-1ra have emerged as prominent biomarkers of persistent fatigue in cross-sectional studies of women several years post chemotherapy. No similar work has identified biomarkers of neurocognitive dysfunction in this patient population, and it is not known if the cytokine links with fatigue, or other behavioral symptoms, exist closer to the diagnosis period or evolve over time as "late effects". In this study, we will address this knowledge gap as we will evaluate this association prior to cancer treatment, and again following treatment completion. We will compare these associations in a minimum of 137 breast cancer patients relative to two comparison groups at pre-treatment, and longitudinally evaluate only the breast cancer group after treatment. Findings are expected to increase our knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects. PUBLIC HEALTH RELEVANCE: Findings are expected to increase knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects.